The Renoir phase 3 study investigates the efficacy of combining rituximab and lenalidomide versus rituximab alone for relapsed/refractory (R/R) follicular lymphoma in elderly patients, in whom treatment options are typically limited. Lenalidomide, known for its direct anti-tumor and antiangiogenic effects, and ability to modulate the tumor-cell microenvironment, presents a viable option, and when combined with […]